Protection induced by early stage vaccination with pandemic influenza virus-like particles.
Identifieur interne : 000848 ( Main/Exploration ); précédent : 000847; suivant : 000849Protection induced by early stage vaccination with pandemic influenza virus-like particles.
Auteurs : Gi-Ja Lee [Corée du Sud] ; Fu-Shi Quan [Corée du Sud]Source :
- Vaccine [ 1873-2518 ] ; 2016.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (sang), Anticorps neutralisants (sang), Cytokines (immunologie), Femelle, Immunité humorale, Immunoglobuline G (sang), Infections à Orthomyxoviridae (), Poumon (virologie), Protéines de la matrice virale (immunologie), Souris, Souris de lignée BALB C, Sous-type H1N1 du virus de la grippe A, Tests d'inhibition de l'hémagglutination, Vaccins antigrippaux (immunologie), Vaccins à pseudo-particules virales (immunologie).
- MESH :
- immunologie : Cytokines, Protéines de la matrice virale, Vaccins antigrippaux, Vaccins à pseudo-particules virales.
- sang : Anticorps antiviraux, Anticorps neutralisants, Immunoglobuline G.
- virologie : Poumon.
- Animaux, Femelle, Immunité humorale, Infections à Orthomyxoviridae, Souris, Souris de lignée BALB C, Sous-type H1N1 du virus de la grippe A, Tests d'inhibition de l'hémagglutination.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Cytokines (immunology), Female, Hemagglutination Inhibition Tests, Immunity, Humoral, Immunoglobulin G (blood), Influenza A Virus, H1N1 Subtype, Influenza Vaccines (immunology), Lung (virology), Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections (prevention & control), Vaccines, Virus-Like Particle (immunology), Viral Matrix Proteins (immunology).
- MESH :
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral, Immunoglobulin G.
- chemical , immunology : Cytokines, Influenza Vaccines, Vaccines, Virus-Like Particle, Viral Matrix Proteins.
- prevention & control : Orthomyxoviridae Infections.
- virology : Lung.
- Animals, Female, Hemagglutination Inhibition Tests, Immunity, Humoral, Influenza A Virus, H1N1 Subtype, Mice, Mice, Inbred BALB C.
Abstract
The 2009 worldwide influenza pandemic emphasized the need for new approaches to develop emergency vaccines. In this study, a virus-like particle vaccine comprised of hemagglutinin (HA) and M1 from the pandemic influenza virus A/California/04/09 were used and its ability to induce protective immunity during the early stage of vaccination was assessed in a mouse model. A single intramuscular vaccination with virus-like particles (VLPs) provided protection on days 4 and 7 post-vaccination against lethal virus challenge with only moderate body weight loss. VLP vaccination induced significantly higher IgG antibody responses and high hemagglutinin inhibition (HAI) titers on day 4 post-vaccination. A predominant IgG2a antibody response and viral neutralizing antibodies were induced on day 7. These immune responses were closely correlated with protection. Lung virus titers decreased significantly on day 7 compared to those on day 4 post-vaccination. The lung virus titer on day 4 post-vaccination also decreased significantly compared to that of the naïve control. These results demonstrate that VLP vaccination confers effective protection during the early stage after vaccination in a mouse model.
DOI: 10.1016/j.vaccine.2016.06.011
PubMed: 27317263
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000523
- to stream PubMed, to step Curation: 000523
- to stream PubMed, to step Checkpoint: 000473
- to stream Ncbi, to step Merge: 001B66
- to stream Ncbi, to step Curation: 001B66
- to stream Ncbi, to step Checkpoint: 001B66
- to stream Main, to step Merge: 000850
- to stream Main, to step Curation: 000848
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protection induced by early stage vaccination with pandemic influenza virus-like particles.</title><author><name sortKey="Lee, Gi Ja" sort="Lee, Gi Ja" uniqKey="Lee G" first="Gi-Ja" last="Lee">Gi-Ja Lee</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biomedical Engineering, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Biomedical Engineering, College of Medicine, Kyung Hee University, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Quan, Fu Shi" sort="Quan, Fu Shi" uniqKey="Quan F" first="Fu-Shi" last="Quan">Fu-Shi Quan</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul, Republic of Korea. Electronic address: fsquan@khu.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27317263</idno><idno type="pmid">27317263</idno><idno type="doi">10.1016/j.vaccine.2016.06.011</idno><idno type="wicri:Area/PubMed/Corpus">000523</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000523</idno><idno type="wicri:Area/PubMed/Curation">000523</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000523</idno><idno type="wicri:Area/PubMed/Checkpoint">000473</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000473</idno><idno type="wicri:Area/Ncbi/Merge">001B66</idno><idno type="wicri:Area/Ncbi/Curation">001B66</idno><idno type="wicri:Area/Ncbi/Checkpoint">001B66</idno><idno type="wicri:Area/Main/Merge">000850</idno><idno type="wicri:Area/Main/Curation">000848</idno><idno type="wicri:Area/Main/Exploration">000848</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Protection induced by early stage vaccination with pandemic influenza virus-like particles.</title><author><name sortKey="Lee, Gi Ja" sort="Lee, Gi Ja" uniqKey="Lee G" first="Gi-Ja" last="Lee">Gi-Ja Lee</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biomedical Engineering, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Biomedical Engineering, College of Medicine, Kyung Hee University, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Quan, Fu Shi" sort="Quan, Fu Shi" uniqKey="Quan F" first="Fu-Shi" last="Quan">Fu-Shi Quan</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul, Republic of Korea. Electronic address: fsquan@khu.ac.kr.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Viral (blood)</term><term>Cytokines (immunology)</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Immunity, Humoral</term><term>Immunoglobulin G (blood)</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines (immunology)</term><term>Lung (virology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>Vaccines, Virus-Like Particle (immunology)</term><term>Viral Matrix Proteins (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (sang)</term><term>Anticorps neutralisants (sang)</term><term>Cytokines (immunologie)</term><term>Femelle</term><term>Immunité humorale</term><term>Immunoglobuline G (sang)</term><term>Infections à Orthomyxoviridae ()</term><term>Poumon (virologie)</term><term>Protéines de la matrice virale (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins à pseudo-particules virales (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Cytokines</term><term>Influenza Vaccines</term><term>Vaccines, Virus-Like Particle</term><term>Viral Matrix Proteins</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Cytokines</term><term>Protéines de la matrice virale</term><term>Vaccins antigrippaux</term><term>Vaccins à pseudo-particules virales</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term><term>Immunoglobuline G</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Immunity, Humoral</term><term>Influenza A Virus, H1N1 Subtype</term><term>Mice</term><term>Mice, Inbred BALB C</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Femelle</term><term>Immunité humorale</term><term>Infections à Orthomyxoviridae</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Tests d'inhibition de l'hémagglutination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The 2009 worldwide influenza pandemic emphasized the need for new approaches to develop emergency vaccines. In this study, a virus-like particle vaccine comprised of hemagglutinin (HA) and M1 from the pandemic influenza virus A/California/04/09 were used and its ability to induce protective immunity during the early stage of vaccination was assessed in a mouse model. A single intramuscular vaccination with virus-like particles (VLPs) provided protection on days 4 and 7 post-vaccination against lethal virus challenge with only moderate body weight loss. VLP vaccination induced significantly higher IgG antibody responses and high hemagglutinin inhibition (HAI) titers on day 4 post-vaccination. A predominant IgG2a antibody response and viral neutralizing antibodies were induced on day 7. These immune responses were closely correlated with protection. Lung virus titers decreased significantly on day 7 compared to those on day 4 post-vaccination. The lung virus titer on day 4 post-vaccination also decreased significantly compared to that of the naïve control. These results demonstrate that VLP vaccination confers effective protection during the early stage after vaccination in a mouse model.</div></front></TEI><affiliations><list><country><li>Corée du Sud</li></country><region><li>Région capitale de Séoul</li></region><settlement><li>Séoul</li></settlement></list><tree><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Lee, Gi Ja" sort="Lee, Gi Ja" uniqKey="Lee G" first="Gi-Ja" last="Lee">Gi-Ja Lee</name></region><name sortKey="Quan, Fu Shi" sort="Quan, Fu Shi" uniqKey="Quan F" first="Fu-Shi" last="Quan">Fu-Shi Quan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000848 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000848 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27317263
|texte= Protection induced by early stage vaccination with pandemic influenza virus-like particles.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27317263" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |